PMID- 30524369
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 9
DP  - 2018
TI  - Vascular Endothelial Growth Factor (VEGF) Induced Downstream Responses to 
      Transient Receptor Potential Vanilloid 1 (TRPV1) and 3-Iodothyronamine (3-T(1)AM) 
      in Human Corneal Keratocytes.
PG  - 670
LID - 10.3389/fendo.2018.00670 [doi]
LID - 670
AB  - This study was undertaken to determine if crosstalk among the transient receptor 
      potential (TRP) melastatin 8 (TRPM8), TRP vanilloid 1 (TRPV1), and vascular 
      endothelial growth factor (VEGF) receptor triad modulates VEGF-induced Ca(2+) 
      signaling in human corneal keratocytes. Using RT-PCR, qPCR and 
      immunohistochemistry, we determined TRPV1 and TRPM8 gene and protein coexpression 
      in a human corneal keratocyte cell line (HCK) and human corneal cross sections. 
      Fluorescence Ca(2+) imaging using both a photomultiplier and a single cell 
      digital imaging system as well as planar patch-clamping measured relative 
      intracellular Ca(2+) levels and underlying whole-cell currents. The TRPV1 agonist 
      capsaicin increased both intracellular Ca(2+) levels and whole-cell currents, 
      while the antagonist capsazepine (CPZ) inhibited them. VEGF-induced Ca(2+) 
      transients and rises in whole-cell currents were suppressed by CPZ, whereas a 
      selective TRPM8 antagonist, AMTB, increased VEGF signaling. In contrast, an 
      endogenous thyroid hormone-derived metabolite 3-Iodothyronamine (3-T(1)AM) 
      suppressed increases in the VEGF-induced current. The TRPM8 agonist menthol 
      increased the currents, while AMTB suppressed this response. The VEGF-induced 
      increases in Ca(2+) influx and their underlying ionic currents stem from 
      crosstalk between VEGFR and TRPV1, which can be impeded by 3-T(1)AM-induced TRPM8 
      activation. Such suppression in turn blocks VEGF-induced TRPV1 activation. 
      Therefore, crosstalk between TRPM8 and TRPV1 inhibits VEGFR-induced activation of 
      TRPV1.
FAU - Turker, Ersal
AU  - Turker E
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Garreis, Fabian
AU  - Garreis F
AD  - Department of Functional and Clinical Anatomy, Friedrich Alexander University 
      Erlangen-Nurnberg, Erlangen, Germany.
FAU - Khajavi, Noushafarin
AU  - Khajavi N
AD  - Institut fur Experimentelle Padiatrische Endokrinologie, 
      Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin, 
      Humboldt-Universitat zu Berlin, and Berlin Institute of Health, Berlin, Germany.
AD  - Walter Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian 
      University of Munich, Munich, Germany.
FAU - Reinach, Peter S
AU  - Reinach PS
AD  - School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, 
      China.
FAU - Joshi, Pooja
AU  - Joshi P
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Brockmann, Tobias
AU  - Brockmann T
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
AD  - Berlin Institute of Health (BIH), Berlin, Germany.
FAU - Lucius, Alexander
AU  - Lucius A
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Ljubojevic, Nina
AU  - Ljubojevic N
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Turan, Elizabeth
AU  - Turan E
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Cooper, Drew
AU  - Cooper D
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Schick, Felix
AU  - Schick F
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Reinholz, Rob
AU  - Reinholz R
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Pleyer, Uwe
AU  - Pleyer U
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
FAU - Kohrle, Josef
AU  - Kohrle J
AD  - Institut fur Experimentelle Endokrinologie, Charite-Universitatsmedizin Berlin, 
      Corporate Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and 
      Berlin Institute of Health, Berlin, Germany.
FAU - Mergler, Stefan
AU  - Mergler S
AD  - Klinik fur Augenheilkunde, Charite-Universitatsmedizin Berlin, Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20181122
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC6262029
OTO - NOTNLM
OT  - 3-iodothyronamine
OT  - human corneal keratocytes
OT  - intracellular Ca2+
OT  - planar patch-clamp technique
OT  - thyronamine
OT  - transient receptor potential channel melastatin 8
OT  - transient receptor potential channel vanilloid 1
OT  - vascular endothelial growth factor
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/01/01
CRDT- 2018/12/08 06:00
PHST- 2018/06/12 00:00 [received]
PHST- 2018/10/26 00:00 [accepted]
PHST- 2018/12/08 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2018.00670 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2018 Nov 22;9:670. doi: 10.3389/fendo.2018.00670. 
      eCollection 2018.